OncLive Insights

OncLive Insights

Series

All
All
Experts featured in this series

How I Treat: Precision Sequencing for EGFR-Mutated NSCLC and Exon 20 Insertion

Zofia Piotrowska, MD, MHS, and Lyudmila Bazhenova, MD, FASCO, discuss molecular testing, treatment sequencing, and adverse event monitoring in epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer, focusing on acquired MET-driven resistance after frontline osimertinib and EGFR exon 20 insertion disease that progresses after chemotherapy plus amivantamab.

2 experts in this series

My Treatment Approach: Optimizing Treatment Strategies for Relapsed/Refractory Multiple Myeloma

In this OncLive® My Treatment Approach program, Dr. Joshua Richter and Dr. Surbhi Sidana discuss the evolving treatment landscape for relapsed/refractory multiple myeloma, with a focus on BCMA-directed therapies, including antibody-drug conjugates (ADCs), CAR T-cell therapies, and bispecific antibodies. They examine how prior treatment exposure, refractoriness, disease biology, and patient preferences influence treatment selection and sequencing at relapse. The discussion reviews clinical evidence from the DREAMM-7 and DREAMM-8 trials and considers the relative efficacy, safety profiles, and practical considerations associated with different BCMA-directed approaches. Dr. Sidana also shares strategies for recognizing and managing belantamab mafodotin-associated ocular toxicity, including patient counseling, ophthalmic monitoring, dose modifications, and multidisciplinary coordination. The experts further explore infrastructure and supportive care requirements for delivering these therapies in community and academic settings. Through clinical scenarios, they address patient selection, treatment access, caregiver support, and emerging evidence for ADC-based combinations in newly diagnosed multiple myeloma.

Reassessing Continuous vs Fixed-Duration Therapy in Treatment-Naive Chronic Lymphocytic Leukemia

Sameh Gaballa, MD, of Moffitt Cancer Center; M. Yair Levy, MD, of Texas Oncology–Baylor Charles A. Sammons Cancer Center; and Andrew H. Lipsky, MD, of Columbia University Irving Medical Center, discuss how they choose between continuous Bruton tyrosine kinase inhibitor therapy and fixed-duration, venetoclax-based therapy for patients with treatment-naive chronic lymphocytic leukemia, including genomic testing, long-term trial data, cardiac and infection safety, retreatment, the first-line role of pirtobrutinib, and next-generation agents.

Beyond the Frontline in EGFR-Mutant NSCLC: MET-Driven Resistance and Exon 20 Insertions After ESMO 2026

Julia Rotow, MD, of Dana-Farber Cancer Institute, and Ticiana Leal, MD, of Winship Cancer Institute of Emory University, discuss how they evaluate and treat patients with EGFR-mutant non–small cell lung cancer who progress on first-line osimertinib, including rebiopsy, local therapy, the phase 3 SAFFRON data for osimertinib plus savolitinib in MET-driven resistance, and all-comer options such as antibody-drug conjugates, and how they view the first-line and later-line landscape for EGFR exon 20 insertion–mutated disease after the PAPILLON, WU-KONG28, REZILIENT3, and FURVENT trials.

2 experts are featured in this series

Updates in Gastrointestinal Oncology: Key Data From the 2026 ESMO Congress

Experts in gastrointestinal oncology review key data from the ESMO Congress across gastroesophageal, pancreatic and rectal cancers, discussing what each finding means for practice now and where the field is heading. In HER2-positive gastroesophageal adenocarcinoma, final analyses of HERIZON-GEA-01 show an overall survival benefit for zanidatamab-based regimens over trastuzumab plus chemotherapy. The panel sees this as support for the triplet with tislelizumab as a first-line option. In pancreatic cancer, subgroup analyses of RASolute 302 reinforce daraxonrasib as a standard of care in previously treated metastatic disease. The panel covers how to interpret the RAS wild-type results and gives practical advice on managing skin toxicity. AMPLIFY-7P did not meet its primary end point but still offers lessons on how well the vaccine triggers an immune response, how well circulating tumor DNA predicts outcomes, and the need for combination strategies after surgery. Finally, AZUR-1 highlights the promise of neoadjuvant dostarlimab for organ preservation in mismatch repair-deficient rectal cancer. It also raises the challenges of standardizing how clinical complete response is defined and how patients are monitored.

Optimizing Care Coordination for CAR-T Therapy in DLBCL: Bridging the Gap Between Academic Centers and Community Practice

In this OncLive Insights program, Dr. Mark Dailey, Dr. Caron A. Jacobson, and NP Stefanie Sigmund discuss strategies to improve access to chimeric antigen receptor (CAR) T-cell therapy and coordinate care for patients with diffuse large B-cell lymphoma (DLBCL). The discussion explores identifying appropriate candidates for CAR T-cell therapy, initiating timely referrals, and addressing misconceptions about eligibility, including considerations for older patients and those with comorbidities. The panel examines communication between community oncology practices and academic CAR T-cell centers, management of patients awaiting treatment, and barriers related to travel, lodging, finances, and caregiver support. Additional topics include bridging therapy, outpatient treatment pathways, post-infusion monitoring, and the implications of the FDA’s 2025 elimination of Risk Evaluation and Mitigation Strategies (REMS) requirements. The experts also discuss structured care transitions, monitoring for late complications, long-term follow-up, and a potential hub-and-spoke model to strengthen collaboration and reduce the burden on patients and caregivers.

My Treatment Approach: Individualizing Treatment Selection and Sequencing in Platinum-Resistant Ovarian Cancer

Rachel N. Grisham, MD, of Memorial Sloan Kettering Cancer Center in New York, New York, and Ritu Salani, MD, MBA, of the David Geffen School of Medicine at UCLA in Los Angeles, California, discuss how they individualize treatment selection and sequencing for patients with platinum-resistant ovarian cancer, covering biomarker testing, the phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel, day-to-day management of adverse events, and two patient cases.

Navigating the Evolving Treatment Landscape of Relapsed/Refractory Chronic Lymphocytic Leukemia

In this OncLive Insights program, Dr. Mazyar Shadman and Dr. Jennifer J. Huang discuss the evolving treatment landscape for relapsed/refractory chronic lymphocytic leukemia (CLL), focusing on treatment selection, sequencing, and the integration of chimeric antigen receptor (CAR) T-cell therapy. They review how prior treatment exposure, duration of response, and reasons for discontinuation, including disease progression and intolerance, influence subsequent treatment decisions. The discussion explores treatment options following covalent Bruton tyrosine kinase (BTK) inhibitor therapy, including pirtobrutinib and venetoclax-based regimens, as well as the role of resistance mutations and emerging investigational therapies. The experts emphasize timely referral to specialized centers for CAR T-cell evaluation and discuss patient selection, clinical evidence, disease control, and bridging strategies. A clinical scenario illustrates treatment planning following progression on multiple therapies. The program concludes with a discussion of post-CAR T-cell therapy toxicity management, long-term monitoring, coordination between specialized centers and referring clinicians, and the importance of early referral.

2 experts

Individualizing Frontline CLL: Choosing Between Continuous and Fixed-Duration BTK Inhibitor-Based Strategies

Frontline management of chronic lymphocytic leukemia (CLL) has shifted from chemoimmunotherapy to targeted regimens, leaving clinicians to choose between continuous and fixed-duration approaches. In this program, expert faculty compare covalent and noncovalent Bruton tyrosine kinase (BTK) inhibitors, including acalabrutinib, zanubrutinib, and pirtobrutinib, and weigh venetoclax plus obinutuzumab against all-oral acalabrutinib plus venetoclax from the AMPLIFY trial. The discussion covers low tumor lysis risk with a BTK inhibitor lead-in, infusion reactions, infection and cardiac toxicity with continuous therapy, and how patient preference, comorbidities, cost, and access shape decisions. Through patient cases, the faculty address high-risk chromosomal aberrations, the role of an obinutuzumab triplet in younger patients with unmutated immunoglobulin heavy chain variable region (IGHV) disease, retreatment after time-limited therapy, BTK inhibitor sequencing, and emerging head-to-head trials. They conclude that most patients can now receive individualized, well-tolerated therapy.

A Multidisciplinary Approach to Neuroendocrine Tumors: From Somatostatin Receptor Imaging to Radioligand Therapy

Daniel M. Halperin, MD, of Winship Cancer Institute of Emory University; Jonathan R. Strosberg, MD, of Moffitt Cancer Center; and Simron Singh, MD, MPH, of Sunnybrook Odette Cancer Centre, discuss the multidisciplinary diagnosis and management of neuroendocrine tumors, from classification and somatostatin receptor PET imaging to peptide receptor radionuclide therapy and the alpha emitters on the horizon.

2 experts in this series

First-Line and Later-Line Strategies in EGFR Exon 20 Insertion–Mutated NSCLC

Lyudmila Bazhenova, MD, of UC San Diego Moores Cancer Center, and Pasi A. Jänne, MD, PhD, of Dana-Farber Cancer Institute, discuss how EGFR exon 20 insertions are identified in non–small cell lung cancer, how they weigh amivantamab plus chemotherapy against newer oral options such as sunvozertinib, zipalertinib, and firmonertinib in the first-line and later-line settings, and how central nervous system activity, toxicity, dosing, and sequencing shape treatment selection.

3 experts are featured in this series

The Evolving Treatment Landscape in TGCT

R. Lor Randall, MD, FACS, of UC Davis Health; Dale R. Shepard, MD, PhD, of Cleveland Clinic; and Alexander B. Christ, MD, of UCLA Health, discuss how tenosynovial giant cell tumor (TGCT) is recognized and referred, how they choose between surgery and colony-stimulating factor 1 receptor (CSF1R) inhibitors, what the phase 3 MANEUVER trial showed for the investigational agent pimicotinib, and how long patients may need treatment.

3 experts are featured in this series

First-Line Treatment Strategies in EGFR-Mutated NSCLC: Managing Toxicity and Supporting Treatment Continuity

Dr. Jonathan Riess from UC Davis Comprehensive Cancer Center moderated a discussion with Dr. Mary Jo Fidler from Rush University Medical Center and Dr. Matthew Gumbleton from Huntsman Cancer Institute on first-line treatment selection and proactive toxicity management for patients with EGFR-mutated non-small cell lung cancer (NSCLC).

With two combination regimens now demonstrating overall survival benefit over osimertinib monotherapy, including amivantamab-lazertinib (MARIPOSA) and osimertinib plus carboplatin-pemetrexed (FLAURA2), the discussion addresses how to individualize frontline EGFR-mutated NSCLC treatment selection based on TP53 co-mutation status, CNS metastases, and patient-specific factors. The COCOON dermatologic prophylaxis protocol, COPERNICUS study design, subcutaneous amivantamab, dose modification strategies, and patient education frameworks are covered in depth. Two clinical scenarios illustrate shared decision-making for a never-smoking woman with TP53 co-mutation and a patient with CNS metastases, with closing practice pearls emphasizing frontline treatment intensification for the majority of patients with EGFR-mutated advanced NSCLC.

2 experts in this video series

2026 WCLC Through a Biomarker Lens The Biomarker Behind the Data: EGFR and KRAS G12C

Two medical oncologists recording at the 2026 World Conference on Lung Cancer (WCLC) in Seoul use new evidence as a way into 2 biomarkers in non-small cell lung cancer (NSCLC). The program covers what EGFR and KRAS G12C results tell a clinician beyond treatment selection, the EGFR result at progression and the updated HARMONi overall survival analysis, AMIGO-1 and COPERNICUS data, EGFR and central nervous system disease, KRAS G12C in practice and neoadjuvant NAUTIKA1 data, broad molecular profiling from diagnosis, and closing clinical pearls.

First-Line Options in EGFR-Mutated Advanced NSCLC: Selecting and Initiating Subcutaneous Amivantamab Plus Lazertinib With Prophylactic Strategies

Edgardo Santos, MD, FACP, FASCO, of Starling Oncology, and Wade Iams, MD, MSCI, of Tennessee Oncology, work through how they choose among first-line options for EGFR exon 19 deletion and L858R advanced non–small cell lung cancer. Both favor a combination regimen over third-generation tyrosine kinase inhibitor monotherapy, citing the overall survival advantage seen with amivantamab plus lazertinib in MARIPOSA and with platinum-based chemotherapy plus osimertinib in FLAURA2. Dr Santos cites 3-year intracranial progression-free survival of 36% with the combination vs 18% with osimertinib in MARIPOSA as the reason he favors it when brain metastases are present. Dr Iams describes the pragmatic COPERNICUS study, which pairs every-4-week subcutaneous amivantamab with prophylactic anticoagulation and enhanced dermatologic prophylaxis, and reports rash falling from roughly 50% to 60% down to 20% to 30%. Dr Santos details his day 1 order set, and across 2 cases the faculty weigh brain metastases, chronic kidney disease, prior thrombosis, travel distance, and patient preference.

Long-Term Survival Data in EGFR-Mutated NSCLC: Applying New Evidence Across the Treatment Continuum

Dr. Roy Herbst from Dartmouth Cancer Center and Dr. Samuel Kareff from Lynn Cancer Institute discuss how emerging long-term survival data are reshaping treatment decisions across the continuum of EGFR-mutated non-small cell lung cancer (NSCLC), from the adjuvant setting through metastatic disease management.

Two clinical scenarios are discussed. The first presents a patient with resected early-stage EGFR exon 19 deletion NSCLC who received immunotherapy before molecular results returned, illustrating the pitfalls of acting on PD-L1 status alone and the importance of completing next-generation sequencing before initiating systemic therapy. The second presents a patient with metastatic EGFR-mutated NSCLC and central nervous system metastases, exploring frontline combination therapy selection, local consolidative therapy considerations, post-progression biopsy strategy, and resistance mechanisms including small cell transformation and MET amplification. The 8-year ADAURA overall survival data, adjuvant osimertinib treatment adherence strategies, neoadjuvant approaches, and future directions including vaccines and leptomeningeal disease management are discussed throughout.

2 experts are featured in this series

Optimizing Frontline and Early Relapse Management in Multiple Myeloma: APP Perspectives

This OncLive® Insights program explores evolving approaches to the management of multiple myeloma across frontline and early relapse settings, with a focus on practical considerations for advanced practice providers. Jill Burke, NP, and Tanika Pittman, APRN, discuss the growing role of quadruplet regimens in newly diagnosed multiple myeloma, including patient selection, treatment goals, multidisciplinary assessment, and strategies for educating patients and caregivers. The discussion also addresses treatment duration, toxicity monitoring, infection prevention, supportive care, adherence, shared decision-making, and the role of minimal residual disease assessment in communicating treatment response. Faculty share practical perspectives on anti-CD38 therapy administration, subcutaneous delivery options, clinic workflow, and reducing treatment burden. The conversation then transitions to early relapse, highlighting individualized treatment selection, sequencing considerations, and preparation for teclistamab plus daratumumab, including step-up dosing, safety monitoring, infection risk, and care coordination. The program concludes with practical clinical pearls on the evolving role of APPs in multiple myeloma care.

2 experts in this series

EGFR-Mutated NSCLC: Optimizing Treatment from First-Line Selection to Second-Line Sequencing

Treatment of EGFR-mutated advanced non-small cell lung cancer has moved well past a single tyrosine kinase inhibitor, and the decisions have grown correspondingly harder. This series works through them in sequence. It opens with risk stratification, including how often TP53 co-mutations appear and what they should change, then examines the clinical and molecular factors that determine whether a patient starts on monotherapy or a combination, weighing tumor burden and metastatic sites against age, comorbidities, and what a patient is willing to accept. Second-line discussion covers platinum rechallenge, the choice between datopotamab deruxtecan and amivantamab plus chemotherapy in the absence of a head-to-head trial, and what emerging antibody-drug conjugate combinations would need to demonstrate to change practice. Later segments turn to the toxicities that actually interrupt treatment, the multidisciplinary support required to manage them, and the testing, trial access, and reimbursement barriers that shape care outside academic centers.

2 experts are featured in this series

Optimizing Treatment Selection and Sequencing in Advanced EGFR-Mutated NSCLC: Balancing Efficacy, Toxicity, and Emerging Evidence

Dr. Sandip Patel (UC San Diego, Moores Cancer Center) and Dr. Deborah Doroshow (Tisch Cancer Center, Icahn School of Medicine at Mount Sinai) take a practical look at how treatment selection and sequencing are evolving in advanced EGFR-mutated non-small cell lung cancer (NSCLC). The discussion covers frontline regimen selection between osimertinib monotherapy, FLAURA2, and MARIPOSA, including the role of clinical features, ctDNA, CNS metastases, TP53 co-mutation, and treatment burden. The experts review subcutaneous amivantamab and the COCOON regimen, sequential planning across lines, second-line options including COMPEL and MARIPOSA-2, the role of Dato-DXd and ADC toxicity management, MET-directed resistance, and key takeaways on precision diagnostics and treatment tolerability. Tailored for community and academic oncologists, BCOPs, and the multidisciplinary thoracic oncology team.

2 experts are featured in this series

Sequencing CAR T-Cell Therapy in Early Relapsed/Refractory Multiple Myeloma: Optimizing Patient Selection, Bridging, and Future Treatment Strategies

In this OncLive® Insights program, Dr. Joshua Richter and Dr. Doris Hansen discuss the evolving role of CAR T-cell therapy in early relapsed/refractory multiple myeloma, with a focus on treatment sequencing, patient selection, bridging therapy, and emerging cellular therapy approaches. The experts examine how the expanding availability of BCMA-directed CAR T-cell therapies and bispecific antibodies is influencing treatment decisions at first relapse, including considerations around using CAR T-cell therapy earlier in the disease course. They discuss the importance of early referral to cellular therapy centers, appropriate patient selection, and disease control before CAR T-cell infusion. The conversation also explores how bridging therapy can help optimize patients for treatment, including strategies to balance disease control, T-cell fitness, efficacy, and toxicity risk. Dr. Richter and Dr. Hansen further address treatment sequencing following CAR T-cell therapy and consider emerging approaches such as dual-target CAR T-cell therapies, GPRC5D-directed cellular therapies, in vivo CAR T-cell platforms, and allogeneic CAR T-cell therapies.

3 experts are featured in this series

Real-World Evidence: Optimizing Patient Selection for CAR T-Cell Therapy in Large B-Cell Lymphoma

This OncLive® Insights program explores how real-world evidence (RWE) is shaping the use of CAR T-cell therapy in relapsed or refractory large B-cell lymphoma (LBCL). Dr. Megan Melody, Dr. Miguel-Angel Perales, and Dr. Nirav Shah discuss the evolving role of the three FDA-approved CD19-directed CAR T-cell therapies, including their positioning across the second- and later-line settings and how RWE complements pivotal clinical trial data. The panel examines how clinicians can use real-world data to assess CAR T-cell candidacy beyond traditional trial eligibility criteria, considering age, comorbidities, performance status, disease burden, geriatric vulnerabilities, and practical support systems. The discussion also addresses timely referral, bridging therapy, site-of-care considerations, outpatient delivery, and post-infusion logistics. Throughout the program, the experts highlight how RWE can support individualized treatment decisions and help clinicians identify the right patient for CAR T-cell therapy at the right time.

Optimizing Treatment Sequencing and Long-Term Management in Multiple Myeloma: Insights from Evolving Clinical Evidence

This OncLive Insights program brings together Dr. Hans Lee, Dr. Muhamed Baljevic, and Dr. Prashant Kapoor to discuss the rapidly evolving treatment landscape in multiple myeloma and its implications for clinical practice. The panel examines how advances in quadruplet regimens, CAR T-cell therapy, bispecific antibodies, and emerging immune-based approaches are reshaping treatment strategies across newly diagnosed and relapsed/refractory multiple myeloma. The discussion explores treatment sequencing, continuous versus fixed-duration therapy, de-escalation, MRD-guided decision-making, and the balance between disease control, treatment-related toxicity, quality of life, and patient preferences. The experts also address supportive care and strategies to mitigate infections and cytokine release syndrome, approaches to improving access to T-cell-engaging therapies in community settings, and considerations for sequencing therapies after BCMA-directed treatment. Looking ahead, the panel considers emerging targets, trispecific antibodies, in vivo CAR T-cell approaches, CELMoDs, and other developments that may further transform multiple myeloma management.

3 experts are featured in this series

Supportive Care in Extensive-Stage Small Cell Lung Cancer: Optimizing Myeloprotection Through Multidisciplinary Practice

This OncLive® Insights program examines the evolving role of supportive care in extensive-stage small cell lung cancer (ES-SCLC), with a focus on the clinical burden of chemotherapy-induced myelosuppression (CIM) and its impact on treatment delivery, patient outcomes, and quality of life. Megan May, PharmD, moderates a multidisciplinary discussion with Taylor Praska, PharmD, and Amanda Edmond, PA-C, who explore the challenges associated with hematologic toxicities and the limitations of traditional reactive supportive care approaches. The panel discusses the scientific rationale for proactive myeloprotection, including the mechanism of action and clinical evidence supporting trilaciclib, while reviewing its potential role in preserving bone marrow function during platinum-etoposide-containing chemotherapy. Practical insights are shared on patient selection, treatment planning, workflow integration, multidisciplinary collaboration, and patient education, alongside emerging real-world evidence evaluating hospitalization rates, healthcare resource utilization, and quality-of-life outcomes. Throughout the discussion, the faculty emphasize individualized supportive care strategies that help maintain treatment continuity, minimize chemotherapy-related complications, and optimize the overall care experience for patients with ES-SCLC.

2 experts in this series

How I Treat Relapsed/Refractory Multiple Myeloma: Navigating Treatment Selection, Sequencing, and Personalized Care in an Evolving Therapeutic Landscape

In this OncLive® Insights program, Dr. Joshua Richter and Dr. Marco Davila provide an evidence-based discussion on the evolving management of relapsed/refractory multiple myeloma (RRMM), with a focus on optimizing treatment selection, sequencing, and personalized patient care. The conversation explores how recent clinical evidence is influencing earlier integration of advanced therapies, while emphasizing patient identification, disease risk assessment, and individualized treatment planning. Dr. Richter and Dr. Davila discuss practical considerations that extend beyond efficacy data, including appropriate timing of referral to specialized centers, multidisciplinary collaboration, bridging therapy, and coordination between community and academic practices. Through case-based discussions, they examine real-world approaches to managing patients with standard-risk and high-risk disease, highlighting factors that influence therapeutic decision-making across different clinical scenarios. The program also addresses patient quality of life, caregiver engagement, and remaining challenges in improving access to innovative therapies, providing clinicians with practical, balanced insights for delivering personalized care to patients with relapsed/refractory multiple myeloma.

Experts featured in this series.

Navigating the Evolving Treatment Landscape in EGFR-Mutant NSCLC: Balancing Efficacy, Safety, and Treatment Burden

In this OncLive® News Network program, Dr. Mark Socinski and Dr. Susan Scott discuss the evolving treatment landscape for patients with EGFR-mutant non-small cell lung cancer (NSCLC), highlighting recent advances that are reshaping treatment selection across the continuum of care. The discussion explores emerging clinical evidence supporting first-line treatment strategies, interpretation of progression-free and overall survival outcomes, and considerations for treatment sequencing following disease progression. Drs. Socinski and Scott also examine patient- and disease-specific factors that influence therapeutic decision-making, approaches to managing treatment-related adverse events, and practical strategies for maintaining treatment continuity in clinical practice. Additional topics include mechanisms of resistance, molecular reassessment at progression, the role of emerging therapies, multidisciplinary care, and the impact of treatment complexity, access, and financial burden on patient-centered management of EGFR-mutant NSCLC, with an emphasis on translating evolving evidence into everyday clinical practice.